Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?

Nature Clinical Practice Oncology volume 5, pages 372–373 (2008)Cite this article

Weber DM et al. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357: 2133–2142

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565–1571

    Article  CAS  Google Scholar 

  2. Dimopoulos M et al. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123–2132

    Article  CAS  Google Scholar 

  3. Rajkumar S et al. (2007) A randomized trial of lenalidomide plus high dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group (abstract). Blood 121: 31a

    Google Scholar 

  4. Podar K et al. (2007) The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 20: 597–612

    Article  CAS  Google Scholar 

  5. Chang DH et al. (2006) Enhancement of ligand dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108: 618–621

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. MV Dhodapkar is a Professor of Medicine, Chief of the Section of Hematology and Director of Hematologic Malignancies and DL Cooper is a Professor of Medicine and Clinical Director of the Hematopoietic Stem Cell Program, both at the Yale Cancer Center, CT, USA.,

    Madhav V Dhodapkar & Dennis L Cooper

Authors
  1. Madhav V Dhodapkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dennis L Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Madhav V Dhodapkar.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dhodapkar, M., Cooper, D. Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?. Nat Rev Clin Oncol 5, 372–373 (2008). https://doi.org/10.1038/ncponc1138

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc1138

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing